Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
domvanalimab + zimberelimab + platinum-based doublet
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination regimen consisting of domvanalimab (an Fc-silent monoclonal antibody targeting TIGIT), zimberelimab (a monoclonal antibody targeting PD-1), and a platinum-based chemotherapy doublet (commonly cisplatin or carboplatin combined with a third-generation agent such as pemetrexed, paclitaxel, gemcitabine, vinorelbine, or docetaxel). Domvanalimab and zimberelimab co-inhibit TIGIT and PD-1 pathways, enhancing immune activation against tumors. The platinum-based doublet delivers cytotoxic chemotherapy, standard for first-line treatment in advanced non-small cell lung cancer (NSCLC). This combination is being evaluated as a first-line treatment for metastatic NSCLC (including both squamous and nonsquamous histologies) and for advanced gastrointestinal cancers in late-phase clinical trials[1][2][4][5][6].
- Other names
- domvanalimab + zimberelimab + platinum-doublet chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on domvanalimab + zimberelimab + platinum-based doublet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on domvanalimab + zimberelimab + platinum-based doublet.